A Phase I and Enrichment Study of Low-Dose Metronomic Topotecan and Pazopanib in Pediatric Patients with Recurrent or Refractory Solid Tumours Including CNS Tumours.
Phase of Trial: Phase I
Latest Information Update: 03 May 2019
Price : $35 *
At a glance
- Drugs Topotecan (Primary) ; Pazopanib
- Indications CNS cancer; Neuroblastoma; Rhabdomyosarcoma; Solid tumours
- Focus Adverse reactions
- Acronyms TOPAZ
- 10 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by National Cancer Institute of Canada record.
- 21 Mar 2014 New trial record